{
    "clinical_study": {
        "@rank": "111123", 
        "arm_group": [
            {
                "arm_group_label": "severe acute pancreatitis", 
                "description": "patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis."
            }, 
            {
                "arm_group_label": "Pneumonia", 
                "description": "patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to evaluate the influence of severe acute pancreatitis on the\n      serum level of vancomycin, a glycopeptide antibacterial agent."
        }, 
        "brief_title": "Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Arbitrary Restriction Polymorphism 1", 
        "condition_browse": {
            "mesh_term": [
                "Pancreatitis", 
                "Pneumonia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study was to evaluate the influence of severe acute pancreatitis on the\n      serum level of vancomycin, a glycopeptide antibacterial agent.\n\n      After reviewing more than 6000 clinical charts of patients who received vancomycin therapy\n      and whose serum vancomycin level was monitored between January 2010 and December 2013, we\n      identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and\n      98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The\n      fluorescence polarization immunoassay method was used to measure vancomycin serum trough\n      concentrations in these patients 30 min before the next administration. Using these\n      measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-85years old\n\n          -  vancomycin use \u2265 3days\n\n        Exclusion Criteria:\n\n          -  age <18years old or >85 years old\n\n          -  vancomycin use < 3days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients who used vancomycin and who had diagnosed as severe acute pancreatitis (SAP\n        group), and patients who had diagnosed as pneumonia (pneumonia group) . meanwhile, the\n        fluorescence polarization immunoassay method was used to measure vancomycin serum trough\n        concentrations in these patients 30 min before the next administration."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134665", 
            "org_study_id": "hejuanwin19811119"
        }, 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vancomycin", 
            "severe acute pancreatitis", 
            "Creatinine clearance"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "last_name": "He", 
                "phone": "86-21-64370045", 
                "phone_ext": "662618"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Ruijin Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia", 
        "overall_contact": {
            "email": "hejuanwin@126.com", 
            "last_name": "Juan He", 
            "phone": "86-21-64370045", 
            "phone_ext": "664405"
        }, 
        "overall_official": {
            "affiliation": "Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine", 
            "last_name": "Wan-Hua Yang, Prof.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "vancomycin serum trough concentrations was measured in patients just prior to the next dose at steady-state conditions (approximately after the fourth dose).", 
            "measure": "vancomycin serum trough concentrations in these patients just prior to the next vancomycin serum trough concentrations was measured", 
            "safety_issue": "No", 
            "time_frame": "patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134665"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruijin Hospital", 
            "investigator_full_name": "He Juan", 
            "investigator_title": "Miss", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "the pharmacokinetic parameters was calculated using the Bayesian estimator.", 
            "safety_issue": "No", 
            "time_frame": "patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
        }, 
        "source": "Ruijin Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruijin Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}